CINECA IRIS Institutional Research Information System
IRIS è il sistema di gestione integrata dei dati della ricerca (persone, progetti, pubblicazioni, attività) adottato dall'Università degli Studi di Torino.
AperTO è l'archivio istituzionale Open Access destinato a raccogliere, rendere visibile e conservare la produzione scientifica dell'Università degli Studi di Torino.
EnglishLess than 20-25% of non-small cell lung cancer (NSCLC) patients present with stage I or II disease are best treated by surgical resection. Long-term survival in NSCLC remains poor also in these early stages: the 5-year survival rate of patients who undergo complete surgical resection is only 40 to 50%. The majority of post-surgical relapses are distant metastases with the risk of a local recurrence after complete resection being less than 10%. Postoperative treatments, including chemotherapy, radiotherapy or both, have been widely evaluated during the last decades and, unfortunately, none has demonstrated any significant impact on survival. Data regarding large-scale adjuvant chemotherapy trials, closed for the accrual almost four to five years ago, will be fully available soon and, hopefully, a specific meta-analysis will be performed.
| Titolo: | Adjuvant chemotherapy after complete resection for early stage NSCLC | |
| Autori Riconosciuti: | ||
| Autori: | SCAGLIOTTI G ;NOVELLO S | |
| Data di pubblicazione: | 2003 | |
| Abstract: | Less than 20-25% of non-small cell lung cancer (NSCLC) patients present with stage I or II disease are best treated by surgical resection. Long-term survival in NSCLC remains poor also in these early stages: the 5-year survival rate of patients who undergo complete surgical resection is only 40 to 50%. The majority of post-surgical relapses are distant metastases with the risk of a local recurrence after complete resection being less than 10%. Postoperative treatments, including chemotherapy, radiotherapy or both, have been widely evaluated during the last decades and, unfortunately, none has demonstrated any significant impact on survival. Data regarding large-scale adjuvant chemotherapy trials, closed for the accrual almost four to five years ago, will be fully available soon and, hopefully, a specific meta-analysis will be performed. | |
| Volume: | 42 Suppl 1 | |
| Pagina iniziale: | S47 | |
| Pagina finale: | S51 | |
| Digital Object Identifier (DOI): | 10.1016/S0169-5002(03)00304-0 | |
| Rivista: | LUNG CANCER | |
| Appare nelle tipologie: | 03A-Articolo su Rivista |
File in questo prodotto:
Copyright © 2022